TMO
NYSEMulti-factor composite percentile ranking across peer cohort fundamentals.
TMO — composite score 82/100, grade A. Fair-value band: $265.79 (-63.2% premium).
Cross-sectional ranking across covered U.S. equities
Standalone corporate health, ROIC & margins from SEC filings.
Consensus of active sell-side institutional brokers.
Consensus comparison requires a reported analyst recommendation breakdown.
1-Year Price Performance
Range: 1D · 5D · 1M · 6M · YTD · 1Y · 5Y · ALL
Wall Street Consensus Rating
Sell-side broker recommendations & 12-month target status
Decision Read unavailable
Vantage could not load price history for tmo, so trend, momentum, RSI, and moving averages — the tactical half of the verdict — cannot be computed. No verdict is asserted.
Investor context
TMO demonstrates stable balance sheet solvency and sustainable cash generation.
Health Care, Biotech & Pharmaceuticals Decision Playbook(TMO)
Standard multiples break when applied uniformly across Health Care equities. Vantage quant models calibrate specialized valuation anchors, solvency thresholds, and tailored execution rules for Day Traders, Short-Term Swing Traders, and Long-Term Investors.
Relative 4-factor momentum & valuation for swing traders paired with standalone 6-factor fundamental corporate health for long-term compounders.
Multi-timeframe moving averages (SMA 20/50/200), RSI, and tactical entry signals.
Peer valuation multiples, revenue growth horizons, capital efficiency & solvency.
Sector Peer Cohort
Auto-generated from Vantage peer set